Endocrinology Journal Article

Modified Peptide YY Molecule Attenuates the Activity of NPY/AgRP Neurons and Reduces Food Intake in Male Mice

May 10, 2019

Edward S Jones, Nicolas Nunn, Adam P Chambers, Søren Østergaard, Birgitte S Wulff, Simon M Luckman
Endocrinology, Volume 160, Issue 11, November 2019, Pages 2737–2747
https://doi.org/10.1210/en.2019-00100

Abstract

To study the effects of an analog of the gut-produced hormone peptide YY (PYY3-36), which has increased selectivity for the Y2 receptor; specifically, to record its effects on food intake and on hypothalamic neuropeptide Y/agouti-related peptide (NPY/AgRP) neuron activity. NNC0165-1273, a modified form of the peptide hormone PYY3-36 with potent selectivity at Y2 receptor (>5000-fold over Y1, 1250-fold over Y4, and 650-fold over Y5 receptor), was tested in vivo and in vitro in mouse models. NNC0165-1273 has fivefold lower relative affinity for Y2 compared with PYY3-36, but >250-, 192-, and 400-fold higher selectivity, respectively, for the Y1, Y4, and Y5 receptors. NNC0165-1273 produced a reduction in nighttime feeding at a dose at which PYY3-36 loses efficacy. The normal behavioral satiety sequence observed suggests that NNC0165-1273 is not nauseating and, instead, reduces food intake by producing early satiety. Additionally, NNC0165-1273 blocked ghrelin-induced cFos expression in NPY/AgRP neurons. In vitro electrophysiological recordings showed that, opposite to ghrelin, NNC0165-1273 hyperpolarized NPY/AgRP neurons and reduced action potential frequency. Administration of NNC0165-1273 via subcutaneous osmotic minipump caused a dose-dependent decrease in body weight and fat mass in an obese mouse model. Finally, NNC0165-1273 attenuated the feeding response when NPY/AgRP neurons were activated using ghrelin or more selectively with designer receptors. NNC0165-1273 is nonnauseating and stimulates a satiety response through, at least in part, a direct action on hypothalamic NPY/AgRP neurons. Modification of PYY3-36 to produce compounds with increased affinity to Y2 receptors may be useful as antiobesity therapies in humans.

Read the article


You may also like...

JCEM

New Year, New Look

JCEM
JCEM, the most-cited journal in Endocrinology & Metabolism, has a new look for 2020. Check out the latest published articles and sign-up for advanced article alerts today.

Same Great Science

JCEM, the most-cited journal in Endocrinology & Metabolism, has a new look for 2020. Check out the latest published articles and sign-up for advanced article alerts today.

Thematic Issue

Immuno-endocrinology 2020

immuno-endocrinology
Read our special collection of journal articles, published in 2018-2019, focused on immuno-endocrinology! Curation of the collection was guided by Altmetric Attention Scores and Featured Article designations.

Read our special collection of journal articles, published in 2018-2019, focused on immuno-endocrinology! Curation of the collection was guided by Altmetric Attention Scores and Featured Article designations.

Back to top
Short on time?

We'll come to you...

Get updates on the latest breakthroughs, clinical practice guidelines, and career development opportunities, straight to your inbox

Then take the next step: Set up your free website account and get exclusive access to even more great tools & content!